Phathom Pharmaceuticals reports Q3 2026 profit, strong revenue growth and reaffirms guidance
Phathom Pharmaceuticals announced third‑quarter 2026 net revenues of $84.7 million, a 71% year‑over‑year increase, and posted operating profit for the second straight quarter. The company generated $2.1 million of cash, posted an adjusted EPS of $0.04 beating estimates, and reaffirmed its full‑year revenue guidance of $310‑$325 million while noting a legal challenge to VOQUEZNA’s exclusivity.
Why it matters
The earnings call says the cash generation and operating profit signal a transition to self‑funding operations, which supports the stock’s valuation. Phathom also reaffirmed its FY2026 revenue guidance, giving investors a clear outlook despite the pending BDR Pharmaceuticals lawsuit challenging VOQUEZNA’s exclusivity period (the earnings call transcript notes).
Key facts
- 1Net revenues of $84.7 million investing.com
- 2Revenue grew 71% year‑over‑year investing.com
- 3Adjusted EPS of $0.04, beating a consensus estimate of a $0.10 loss investing.com
- 4Operating profit of $5.8 million finance.yahoo.com
- 5Gross margin of 78% for the quarter finance.yahoo.com
- 6Full‑year 2026 revenue guidance of $310 million to $325 million finance.yahoo.com
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.